# Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pictilisib-for-oestrogen-receptor-positive-aromatase-inhibitor-resistant/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ian E. Krop,Ingrid A. Mayer,Vinod Ganju,Maura N. Dickler,Stephen Johnston,Serafín Morales,Denise A. Yardley,Bohuslav Melichar,Andres Forero‐Torres,Soo Chin Lee,Richard de Boer,Katarína Petráková,Susanne Vallentin,Edith A. Perez,Martine Piccart,Matthew J. Ellis,Eric P. Winer,Steven Gendreau,Mika K. Derynck,Mark R. Lackner,Gallia G. Levy,Jiaheng Qiu,Jing He,Peter Schmid |
| Citations | 300 |
| DOI | 10.1016/s1470-2045(16)00106-6 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2346465624 |
| PMID | 27155741 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Maura N. Dickler](https://scholariq.org/researchers/maura-n-dickler/)
- [Jiaheng Qiu](https://scholariq.org/researchers/jiaheng-qiu/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

## Paper topics

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.